A 47-year-old woman presents with new-onset anxiety, insomnia and mood instability. She has no prior psychiatric history. An SSRI is prescribed but poorly tolerated, and her symptoms persist. Several months later, she developed irregular menses and hot flashes. She asks whether her symptoms could be hormonal — and whether treatment should be approached differently.
Each year in the U.S., nearly 3 million women enter perimenopause or menopause. While menopause-related symptoms affect approximately 50% to 80% of midlife women, only 12% to 25% of women seek treatment, often due to perceptions that symptoms will be dismissed or treatment options are unavailable. This perception is not without merit, especially when it comes to lesser recognized symptoms such as mood changes. Scenarios like this represent an area where care delivery can be more consistent, coordinated, and responsive to patient needs.
Background
Women in midlife face an intersection of biological, psychological and social changes that can affect mental health. Outside of the postpartum period, perimenopause is one of the highest-risk windows for new-onset mood disorders, with approximately 1 in 5 women experiencing major depression. These conditions are often attributed to situational stressors or viewed as temporary, despite their association with meaningful functional impairment and increased long-term health risks, including cardiovascular disease and cognitive decline.
At the same time, a growing body of market data suggests patients are actively seeking solutions — often outside traditional healthcare settings. The global menopause market was valued at $17.8 billion in 2024 and is projected to reach $24.4 billion by 2030. In the U.S., women spend more than $13 billion annually managing menopause symptoms, with more than $10 billion directed toward nonmedical treatments.
This distribution of spending highlights a clear misalignment: Demand for symptom management is substantial, but much of it is being met outside physician-delivered care. For health systems, this represents both unrealized revenue and a missed opportunity to engage patients in evidence-based, longitudinal care during a high-utilization phase of life.
Pathophysiology and clinical presentation
Decades of research demonstrate that sex steroids, including estrogen and progesterone, directly influence central nervous system function. When these hormones fluctuate or decline, mood symptoms may emerge in women with underlying neural sensitivity to hormonal change. Studies suggest that 30% to 40% of women experience depressive or anxiety symptoms during the menopausal transition, with rates as high as 70% among those with a prior psychiatric history.
Clinically, perimenopausal depression is often characterized by prominent mood lability and irritability. Anxiety is equally common and may present for the first time in women without prior psychiatric diagnoses. Importantly, mood symptoms rarely occur in isolation. Vasomotor symptoms, sleep disturbance, and cognitive complaints frequently coexist and have a bidirectional relationship with mood, compounding overall symptom burden.
Treatment approach: Hormones, psychiatric meds or something else?
Management of perimenopausal mood disorders should be individualized, taking into account psychiatric history, hormonal sensitivity, and co-occurring menopausal symptoms.
SSRIs and SNRIs remain first-line treatments, with therapeutic principles consistent with other life stages. In addition to improving mood, these agents may also reduce vasomotor symptoms, offering dual benefits.
Menopausal hormone therapy (MHT) is not approved as a primary treatment for major depressive disorder, as evidence for its use as monotherapy is mixed. However, MHT can play an important adjunctive role, particularly in women with significant vasomotor symptoms that contribute to sleep disruption and mood instability. For many women, combination treatment with antidepressants and MHT may provide more comprehensive symptom relief.
Psychotherapy, particularly cognitive behavioral therapy (CBT), is a well-established and guideline-supported intervention that improves depression, anxiety, sleep, and vasomotor symptoms. Lifestyle interventions—including exercise, sleep optimization, and stress management—as well as mindfulness-based approaches, serve as valuable adjuncts to treatment.
Current gaps and opportunities
Despite the prevalence and impact of menopausal mood disorders, care delivery remains inconsistent. Healthcare leadership has an important role in developing systems that improve identification and management of these conditions.
Actionable strategies include:
- Expanding education and training opportunities in menopause-related care for clinicians and trainees
- Standardizing the use of validated screening tools such as the Menopause Rating Scale (MRS) or Patient Health Questionnaire–9 (PHQ-9) during midlife annual exams
- Strengthening collaborative care models that integrate obstetrics and gynecology, primary care, and behavioral health
- Supporting research initiatives focused on menopause-related mental health
While there is an up-front investment required to implement these system-level improvements, the cost of inaction is substantially greater. In the U.S., untreated menopause-related symptoms are estimated to result in approximately $1.8 billion in lost productivity, according to RAND analysis. Additionally, with 80% of the healthcare workforce being female, menopause-related symptoms directly affect a substantial proportion of clinicians, nurses, and staff within the system itself. Addressing these issues has implications not only for patient care, but also for workforce performance, retention and organizational stability.
Conclusion
Women spend nearly one-third of their lives in menopause. Health systems that do not adequately address menopause-related mood disorders risk overlooking a significant and growing contributor to both clinical burden and healthcare utilization.
Integrating menopause-informed care into existing mental health and primary care frameworks represents a practical opportunity to improve patient outcomes, enhance care delivery, and better align services with patient needs.
Sources:
Steps for leadership section sources
Menopause Practitioner – Search – By Country
Liss, J., Chesnokova, A. & Allen, J.T. Unspoken and Untaught: Addressing the Gap in Menopause Education. Curr Obstet Gynecol Rep 13, 281–288 (2024). https://doi.org/10.1007/s13669-024-00404-y Unspoken and Untaught: Addressing the Gap in Menopause Education | Current Obstetrics and Gynecology Reports | Springer Nature Link
FIGO best practice recommendations for the mental health of women at menopausal age – PubMed
The Economic Impacts of Menopause in the United States
At the Becker's Fall Behavioral Health Summit, taking place November 4–5 in Chicago, behavioral health leaders and executives will explore strategies for expanding access to care, integrating services, addressing workforce challenges and leveraging innovation to improve outcomes across the behavioral health continuum. Apply for complimentary registration now.